Novakand Pharma's SVF Vaccines Merger Faces Medium-Probability Catastrophic EMA Compliance Risk
Novakand Pharma AB's reverse takeover of SVF Vaccines carries a 70% confidence assessment of medium-likelihood catastrophic regulatory risk under EMA oversight. The Nasdaq First North Premier-listed company will inherit SVF Vaccines' full clinical trial, product approval, and manufacturing compliance obligations when the merger completes.
ViaNews Editorial Team (Europe)•